2抑制剂-话题@MedSci

#2抑制剂#

221篇内容 | 4073人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1995623, encodeId=3723199562335, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与全因死亡率, objectType=article, longId=204445, objectId=1c7d204445bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c7d204445bf, replyNumber=0, likeNumber=0, createdTime=2021-05-07, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c7d204445bf, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与全因死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c7d204445bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995611, encodeId=de2919956116d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病, objectType=article, longId=200404, objectId=d860200404a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d860200404a6, replyNumber=0, likeNumber=56, createdTime=2021-01-08, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d860200404a6, moduleTitle=FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d860200404a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995625, encodeId=25d4199562539, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet Rheumatol：TYK2抑制剂PF-06826647治疗银屑病的疗效和安全性, objectType=article, longId=205276, objectId=378a2052e6cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=378a2052e6cd, replyNumber=0, likeNumber=59, createdTime=2021-03-01, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=378a2052e6cd, moduleTitle=Lancet Rheumatol：TYK2抑制剂PF-06826647治疗银屑病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=378a2052e6cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995600, encodeId=5487199560031, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与2型糖尿病患者糖尿病酮症酸中毒风险, objectType=article, longId=193883, objectId=9ea41938837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ea41938837b, replyNumber=0, likeNumber=0, createdTime=2020-06-23, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ea41938837b, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与2型糖尿病患者糖尿病酮症酸中毒风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ea41938837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995622, encodeId=3d4d199562271, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=全球上市BCL-2抑制剂维奈克拉在华获批, objectType=article, longId=204278, objectId=7b322042e8be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b322042e8be, replyNumber=0, likeNumber=67, createdTime=2021-10-29, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b322042e8be, moduleTitle=全球上市BCL-2抑制剂维奈克拉在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b322042e8be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995617, encodeId=c125199561eab, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Clin Cancer Res：SHP2抑制剂TNO155通过阻断RTK信号可增强多种靶向药的疗效, objectType=article, longId=202046, objectId=a60c20204663, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a60c20204663, replyNumber=0, likeNumber=54, createdTime=2021-03-13, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a60c20204663, moduleTitle=Clin Cancer Res：SHP2抑制剂TNO155通过阻断RTK信号可增强多种靶向药的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a60c20204663)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995612, encodeId=76fb1995612ac, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, objectType=article, longId=200423, objectId=5feb2004238f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5feb2004238f, replyNumber=0, likeNumber=84, createdTime=2021-07-01, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5feb2004238f, moduleTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5feb2004238f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995601, encodeId=1e0d19956012b, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=FDA：批准SGLT2抑制剂达格列净治疗射血分数降低心衰, objectType=article, longId=194242, objectId=464e1942427f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=464e1942427f, replyNumber=0, likeNumber=56, createdTime=2021-03-16, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=464e1942427f, moduleTitle=FDA：批准SGLT2抑制剂达格列净治疗射血分数降低心衰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=464e1942427f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995604, encodeId=73da19956044a, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=亚盛医药获得FDA授予第二个孤儿药称号：Bcl-2抑制剂APG-2575治疗华氏巨球蛋白血症, objectType=article, longId=197635, objectId=8f5319e6350c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5319e6350c, replyNumber=0, likeNumber=75, createdTime=2020-10-25, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5319e6350c, moduleTitle=亚盛医药获得FDA授予第二个孤儿药称号：Bcl-2抑制剂APG-2575治疗华氏巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f5319e6350c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995618, encodeId=3b14199561833, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）, objectType=article, longId=202283, objectId=d69920228334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d69920228334, replyNumber=0, likeNumber=69, createdTime=2021-06-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d69920228334, moduleTitle=BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d69920228334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995619, encodeId=d3761995619c2, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JAMA：既能降糖又能保护心血管和肾脏？SGLT2抑制剂真的这么神奇吗？, objectType=article, longId=202549, objectId=a65c202549a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a65c202549a6, replyNumber=0, likeNumber=32, createdTime=2021-03-26, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a65c202549a6, moduleTitle=JAMA：既能降糖又能保护心血管和肾脏？SGLT2抑制剂真的这么神奇吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a65c202549a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995582, encodeId=d526199558246, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=“灵魂砍价”药物还能防痛风？SGLT2抑制剂成“万金油”, objectType=article, longId=186358, objectId=6e021863583f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e021863583f, replyNumber=0, likeNumber=71, createdTime=2020-02-15, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e021863583f, moduleTitle=“灵魂砍价”药物还能防痛风？SGLT2抑制剂成“万金油”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e021863583f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995594, encodeId=109a199559449, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Blood：SGLT2抑制剂依帕列净成功纠正了糖原贮积症Ib的中性粒细胞减少及其功能障碍, objectType=article, longId=192947, objectId=49b619294e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49b619294e48, replyNumber=0, likeNumber=87, createdTime=2021-03-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49b619294e48, moduleTitle=Blood：SGLT2抑制剂依帕列净成功纠正了糖原贮积症Ib的中性粒细胞减少及其功能障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49b619294e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995621, encodeId=2647199562175, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, objectType=article, longId=202961, objectId=601d202961a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601d202961a3, replyNumber=0, likeNumber=0, createdTime=2021-09-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601d202961a3, moduleTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=601d202961a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995606, encodeId=00ce1995606d1, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Circulation：三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比, objectType=article, longId=197924, objectId=487a19e924cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=487a19e924cf, replyNumber=0, likeNumber=73, createdTime=2020-07-28, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=487a19e924cf, moduleTitle=Circulation：三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=487a19e924cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995667, encodeId=63c8199566e11, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, objectType=article, longId=200796, objectId=d03f200e96fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d03f200e96fe, replyNumber=0, likeNumber=119, createdTime=2021-08-10, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d03f200e96fe, moduleTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d03f200e96fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995587, encodeId=298d199558e58, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Seattle Genetics公司的口服HER2抑制剂图卡替尼治疗乳腺癌，获得FDA的优先审查, objectType=article, longId=188169, objectId=0f65188169c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f65188169c3, replyNumber=0, likeNumber=66, createdTime=2021-01-28, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f65188169c3, moduleTitle=Seattle Genetics公司的口服HER2抑制剂图卡替尼治疗乳腺癌，获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f65188169c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995591, encodeId=a8021995591d9, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, objectType=article, longId=190017, objectId=0f0519001e6d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0519001e6d, replyNumber=0, likeNumber=58, createdTime=2020-07-12, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0519001e6d, moduleTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f0519001e6d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995613, encodeId=bc6a199561353, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BMJ：SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险, objectType=article, longId=201239, objectId=bc36201239f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc36201239f3, replyNumber=0, likeNumber=83, createdTime=2021-08-14, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc36201239f3, moduleTitle=BMJ：SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc36201239f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995607, encodeId=0e2c199560ee5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Circulation：三种P2Y12抑制剂、四种服用方式用于ST段抬高型心肌梗死患者的疗效, objectType=article, longId=198976, objectId=9d641989e681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d641989e681, replyNumber=0, likeNumber=60, createdTime=2020-09-14, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d641989e681, moduleTitle=Circulation：三种P2Y12抑制剂、四种服用方式用于ST段抬高型心肌梗死患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d641989e681)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2抑制剂

2020-05-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：SGLT2抑制剂与全因死亡率

2021-05-07

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病

2021-01-08

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet Rheumatol：TYK2抑制剂PF-06826647治疗银屑病的疗效和安全性

2021-03-01

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：SGLT2抑制剂与2型糖尿病患者糖尿病酮症酸中毒风险

2020-06-23

爆笑小医 (审核中...)

前往app查看评论内容

#2抑制剂#

全球上市BCL-2抑制剂维奈克拉在华获批

2021-10-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Clin Cancer Res：SHP2抑制剂TNO155通过阻断RTK信号可增强多种靶向药的疗效

2021-03-13

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病

2021-07-01

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

FDA：批准SGLT2抑制剂达格列净治疗射血分数降低心衰

2021-03-16

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

亚盛医药获得FDA授予第二个孤儿药称号：Bcl-2抑制剂APG-2575治疗华氏巨球蛋白血症

2020-10-25

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）

2021-06-22

docwu2019 (审核中...)

前往app查看评论内容

#2抑制剂#

JAMA：既能降糖又能保护心血管和肾脏？SGLT2抑制剂真的这么神奇吗？

2021-03-26

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

“灵魂砍价”药物还能防痛风？SGLT2抑制剂成“万金油”

2020-02-15

智智灵药 (审核中...)

前往app查看评论内容

#2抑制剂#

Blood：SGLT2抑制剂依帕列净成功纠正了糖原贮积症Ib的中性粒细胞减少及其功能障碍

2021-03-12

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast

2021-09-22

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Circulation：三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比

2020-07-28

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！

2021-08-10

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Seattle Genetics公司的口服HER2抑制剂图卡替尼治疗乳腺癌，获得FDA的优先审查

2021-01-28

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病

2020-07-12

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BMJ：SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险

2021-08-14

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Circulation：三种P2Y12抑制剂、四种服用方式用于ST段抬高型心肌梗死患者的疗效

2020-09-14

科室
- - 订阅+
  - 更多科室
工具
服务